Related references
Note: Only part of the references are listed.Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis
Jeffrey M. Sobell et al.
ACTA DERMATO-VENEREOLOGICA (2016)
Psoriasis and the Risk of Depression in the US Population National Health and Nutrition Examination Survey 2009-2012
Brandon E. Cohen et al.
JAMA DERMATOLOGY (2016)
Risk of depression in women with psoriasis: a cohort study
E. D. Dommasch et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
C. Paul et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatogy Life Quality Index (DLQI): Further Data
M. K. A. Basra et al.
DERMATOLOGY (2015)
The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries
Florence J. Dalgard et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
The International Dermatology Outcome Measures Group: Formation of patient-centered outcome measures in dermatology
Alice B. Gottlieb et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
Kim Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Pruritus and quality of life in moderate-to-severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study
U. Mrowietz et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity
P. H. Schafer et al.
CELLULAR SIGNALLING (2014)
The Prevalence and Odds of Depressive Symptoms and Clinical Depression in Psoriasis Patients: A Systematic Review and Meta-Analysis
Emmilia A. Dowlatshahi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Depression and Anxiety in Psoriatic Disease: Prevalence and Associated Factors
Emily McDonough et al.
JOURNAL OF RHEUMATOLOGY (2014)
Psoriasis prevalence among adults in the United States
Tara D. Rachakonda et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study
Vibeke Strand et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2013)
Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence
Rosa Parisi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Patient-reported Health-related Quality of Life with Apremilast for Psoriatic Arthritis: A Phase II, Randomized, Controlled Study
Vibeke Strand et al.
JOURNAL OF RHEUMATOLOGY (2013)
Definition of treatment goals for moderate to severe psoriasis: a European consensus
U. Mrowietz et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2011)
Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial
M. Lebwohl et al.
BRITISH JOURNAL OF DERMATOLOGY (2010)
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial
Richard G. Langley et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2010)
The PHQ-8 as a measure of current depression in the general population
Kurt Kroenke et al.
JOURNAL OF AFFECTIVE DISORDERS (2009)
European S3-Guidelines on the systemic treatment of psoriasis vulgaris
D. Pathirana et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2009)
US norms for six generic health-related quality-of-life indexes from the national health measurement study
Dennis G. Fryback et al.
MEDICAL CARE (2007)
Preference-based EQ-5D index scores for chronic conditions in the United States
Patrick W. Sullivan et al.
MEDICAL DECISION MAKING (2006)
Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial
GG Krueger et al.
BRITISH JOURNAL OF DERMATOLOGY (2005)
The psychosocial burden of psoriasis
AB Kimball et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2005)
Quality of life in patients with psoriasis: A systematic literature review
J de Korte et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS (2004)
EQ-5D: a measure of health status from the EuroQol Group
R Rabin et al.
ANNALS OF MEDICINE (2001)
The work limitations questionnaire
D Lerner et al.
MEDICAL CARE (2001)
Share Paper
